Exploiting lipotoxicity for the treatment of liver cancer.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
07
04
2021
accepted:
30
06
2021
revised:
11
06
2021
pubmed:
25
7
2021
medline:
6
1
2022
entrez:
24
7
2021
Statut:
ppublish
Résumé
Metabolic alterations occur frequently in solid tumours, but metabolic cancer therapies are limited by the complexity and plasticity of metabolic networks. We could recently show that activation of the liver X receptor alpha (LXRα) and inhibition of a Raf-1-SCD1 protein complex induces an intracellular accumulation of saturated free fatty acids leading to lethal lipotoxicity in tumour cells and allows for an efficient treatment of liver carcinomas.
Identifiants
pubmed: 34302061
doi: 10.1038/s41416-021-01479-7
pii: 10.1038/s41416-021-01479-7
pmc: PMC8608911
doi:
Substances chimiques
Liver X Receptors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1459-1461Informations de copyright
© 2021. The Author(s).
Références
Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature. 2012;491:364–73.
doi: 10.1038/nature11706
Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chem Biol. 2017;24:1161–80.
doi: 10.1016/j.chembiol.2017.08.028
Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22.
doi: 10.1038/s41416-019-0650-z
Reczek CR, Chandel NS. The two faces of reactive oxygen species in cancer. Annu Rev Canc Biol. 2017;1:79–98.
doi: 10.1146/annurev-cancerbio-041916-065808
Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, et al. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. 2013;73:2850–62.
doi: 10.1158/0008-5472.CAN-13-0382-T
Munir R, Lisec J, Swinnen JV, Zaidi N. Lipid metabolism in cancer cells under metabolic stress. Br J Cancer. 2019;120:1090–8.
doi: 10.1038/s41416-019-0451-4
Rudalska R, Harbig J, Snaebjornsson MT, Klotz S, Zwirner S, Taranets L, et al. LXRα activation and Raf inhibition trigger lethal lipotoxicity in liver cancer. Nature Cancer. 2021;2:201–17.
doi: 10.1038/s43018-020-00168-3
Peet DJ, Janowski BA, Mangelsdorf DJ. The LXRs: a new class of oxysterol receptors. Curr Opin Genet Dev. 1998;8:571–5.
doi: 10.1016/S0959-437X(98)80013-0
Hong C, Tontonoz P. Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014;13:433–44.
doi: 10.1038/nrd4280
Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, et al. Role of LXRs in control of lipogenesis. Genes Dev. 2000;14:2831–8.
doi: 10.1101/gad.850400
Kato H, Sakaki K, Mihara K. Ubiquitin-proteasome-dependent degradation of mammalian ER stearoyl-CoA desaturase. J Cell Sci. 2006;119:2342–53.
doi: 10.1242/jcs.02951
Agianian B, Gavathiotis E. Current Insights of BRAF Inhibitors in Cancer. J Med Chem. 2018;61:5775–93.
doi: 10.1021/acs.jmedchem.7b01306
Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat. Med. 2014;20:1138–46.
doi: 10.1038/nm.3679
Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.
doi: 10.1038/nrdp.2016.18
Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599–616.
doi: 10.1038/s41571-018-0073-4
Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut. 2021;70:204–14.
doi: 10.1136/gutjnl-2020-321702
Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–6.
doi: 10.1038/s41586-021-03362-0
Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 2006;5:835–44.
doi: 10.1038/nrd2130